

Shionogi Files Patent Infringement Actions Against MSD in Germany and Japan Asserting Patents Covering HIV Integrase Inhibitors

Osaka, Japan, August 18, 2015 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi” or “the Company”) today announced that Shionogi filed a patent infringement action in district court in Dusseldorf, Germany, and Tokyo, Japan on August 17, 2015, against MSD Sharp & Dohme GmbH and its European group companies, and MSD K.K. (hereafter collectively “MSD”), stating that MSD’s integrase inhibitor Isentress[®] infringes Shionogi’s German patent registration No. DE 60242459.3 and Japanese patent registration No. 5207392.

Shionogi considers its intellectual property to be a vitally important resource and always intend to vigorously defend its rights in that regard.

The patents referenced above are singly held by Shionogi and are not related to joint intellectual property held by Shionogi and GlaxoSmithKline covering the HIV integrase inhibitor Tivicay[®]. Tivicay[®] is manufactured and marketed by ViiV Healthcare around the world.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications Department
Shionogi & Co., Ltd.

Osaka Telephone: +81-6-6209-7885 Fax: +81-6-6229-9596

Tokyo Telephone: +81-3-3406-8164 Fax: +81-3-3406-8099